Part of UT Health San Antonio

Part of UT Health San Antonio

You are here

Anand B. Karnad, MD

Contact

210-450-1000

karnad@uthscsa.edu

Departments & Divisions

Institutes & Centers

Research

Research profile

Anand B Karnad, MD

Professor

Castella Endowed Professor in Aging

Karen Lee and David Zachry Endowed Chair in Women’s Cancer

Dr. Anand Karnad received his medical degree from Madras Medical College at the University of Madras (Chennai), in India. Dr. Karnad is Chief, Division of Hematology-Oncology at the Department of Medicine, and UT Health San Antonio MD Anderson Cancer Center and has been Professor of Medicine here since 2004. He has been an active investigator for the National Cancer Institute Clinical Trials for two decades, including trials designed to prevent and treat a range of cancers. He is principal investigator for the National Clinical Trials System (NCTN) SWOG trials at the Cancer Center. He is Program Director of the Hematology-Oncology Fellowship Training Program and has trained fellows since 1989. His clinical research interests include sarcoma, hematological disorders, and geriatric hematology-oncology. He holds the Castella endowed chair in aging. His career goal is to improve the care of patients with blood disorders and cancer through accelerating the completion of clinical trials and in helping to train the next generation of hematologists and oncologists.

Publications

Parra, A., Karnad, A. B. & Thompson, I. M. Hispanic Accrual on Randomized Cancer Clinical Trials: A Call to Arms. J. Clin. Oncol. 20;32(18):1871-3 (2014). PMID: 24841978; PMCID: PMC4050202

Parsons, H. M., Lathrop, K. I., Schmidt, S., Mazo-Canola, M., Trevino-Jones, J., Speck, H. & Karnad, A. B.  Breast Cancer Treatment Delays in a Majority Minority Community: Is There a Difference? J. Oncol. Pract. 11(2):e144-53 (2014). PMID: 25515722; PMCID: PMC4365298

Rowe, J., Patel, S., Mazo-Canola, M., Parra, A., Goros, M., Michalek, J., Kelly, K., Weitman, S. & Karnad, A.  An evaluation of elderly patients (>/=70years old) enrolled in Phase I clinical trials at UT Health San Antonio-Cancer Therapy Research Center from 2009 to 2011. J. Geriatr. Oncol. 5, 65-70 (2014). PMID: 24484720; PMCID: PMC3914160

 

  • Professional Background

    Education

    • 1989 - Postdoctoral Fellowship - Post-Doctoral Fellowship - Research - William Bosworth Castle Hematology Research Laboratory
    • 1987 - Clinical Fellowship - Post-Doctoral Fellowship - Hematology/Oncology - Boston City Hospital, Boston University School of Medicine
    • 1985 - Residency - Chief Resident - Medicine - Veterans Administration Medical Center
    • 1980 - MD - Medicine - Madras Medical College, University of Madras
    • 1975 - Certificate - Pre-medical - Loyola College

    Appointments

    • 9/2013 - Chief- Division of Hematology Oncology, Karen Lee & David Zachry Chair in Women?s Cancer - Department of Medicine, Mays Cancer Center at UT Health MD Anderson, San Antonio, TX, Medicine, San Antonio
    • 3/2005 - Professor of Medicine and Castella Foundation Endowed Chair in Aging - University of Texas Health Science Center CTRC, Medicine, San Antonio
    • 7/2004 - Professor of Medicine (with Tenure since 2013) - Department of Medicine - Mays Cancer Center at UT Health MD Anderson, San Antonio, TX, Medicine, San Antonio

  • Instruction & Training

    • 6/2017 - 7/2020, Individual Instruction, University of Texas Health Science Center at San Antonio, San Antonio, TX
    • 6/2017 - 7/2020, Individual Instruction, University of Texas Health Science Center at San Antonio, San Antonio, TX
    • 6/2017 - 7/2020, Individual Instruction, University of Texas Health Science Center at San Antonio, San Antonio, TX
    • 6/2017 - 7/2020, Individual Instruction, University of Texas Health Science Center at San Antonio, San Antonio, TX
    • 7/2004 - Present, Clinical Hematology, The University of Texas Health Science Center
    • 7/2004 - Present, Oncology, The University of Texas Health Science Center
    • 7/2004 - Present, Post Graduate Rotation Supervision, UT Health Science Center
    • 7/2004 - Present, Pre-Doctoral Student Supervision, Joe R and Teresa Lozano Long School of Medicine, UT Health, San Antonio

  • Research & Grants

    Clinical Trials, Hematologic Malignancies, Sarcoma

    Experimental and Developmental Therapeutics Program 

    Research profile

  • Publications

      Journal Article

      Karnad AB. ReCAP: Association Between the Number of Suppliers for Critical Antineoplastics and Drug Shortages: Implications for Future Drug Shortages and Treatment Journal of Oncology Practice 2016 Mar;:249-250. 52. Ha CS, Michalek JE, Elledge R, Kelly KR, Ganapathy S, Su H, Jenkins CA, Argiris A, Swords R, Eng TY, Karnad A, Crownover RL, Swanson GP, Goros M, Pollock BH, Yuan ZM. p53-Based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study Mol Oncol 2015 Sep;:163-165. Shumway NM, Dacus JJ, Lathrop KI, Hernandez EP, Miller M, Karnad AB. Use of Milestones and Development of Entrustable Professional Activities in 2 Hematology/Oncology Training Programs J Grad Med Educ 2015 Mar;:101-104. Parsons HM, Lathrop KI, Schmidt S, Mazo-Canola M, Trevino-Jones J, Speck H, Karnad AB. Breast cancer treatment delays in a majority minority community: is there a difference? J Oncol Pract 2015 Mar;11(2):144-153. Karnad AB, Parra A, Thompson IM. Hispanic accrual on randomized cancer clinical trials: a call to arms Journal of Clinical Oncology 2014 Jun;32(18):1871-1873. Karnad AB, Tantiwongkosi B, Yu F, Miller FR. Role of (18)F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma World J Radiology 2014 May;6(5):177-191. Karnad AB, Patel SR, Ketchum NS, Pollock BH, Sarantopoulos J, Weitman S, Mahalingam D. Should we move beyong VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials Journal Gastrointestinal Oncology 2014 May;(2):99-103. Karnad AB, Bansal H, Yihua Q, Iyer SP, Ganapathy S, Proia D, Penalva LO, Uren PJ, Suresh U, Carew JS, Weitman S, Tomlinson GE, Rao MK, Kornblau SM, Bansal S. WTAP is a novel oncogenic protein in acute myeloid leukemia Leukemia 2014 May;28(5):1171-1174. Karnad AB, Rowe J, Patel S, Mazo-Canola M, Parra A, Goros M, Michalek J, Kelly K, Weitman S. An evaluation of elderly patients (≥ 70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011 (In Press) J Geriatric Oncol 2013 Sep;. Karnad AB, Trevino M, Padalecki S, Parra A, Weitman S, Nashawati M, Pollock BH, Ramirez A, Thompson IM. The Development of a Minority Recruitment Plan for Cancer Clinical Trials J community Med Health Educ 2013 Sep;3(5).

      Not Specified

      Chang K, Karnad AB, Zhao S, Freeman JW. Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets Oncotarget 2015 Feb;:3507-3518.

  • Clinical

    Board Certifications

    • American Board of Internal Medicine
    • American Board of Internal Medicine/Hematology